



MEDICAL TIPS

DIABIZ TABLETS

Issue V, No. 19, 2023

Association of Dapagliflozin use with Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients with Heart Failure With and Without Gout: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER

Javed HB, et al., JAMA Cardiol. 2023; 8(4):386-393.

- Gout is a common comorbidity in heart failure (HF) patients, and Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers uric acid levels, may lessen the incidence of gout.
- The present study assessed the effects of Dapagliflozin in patients with HF with and without gout and on the introduction of new uric acid-lowering therapy and colchicine.
- In patients with and without gout, Dapagliflozin equally decreased the risk of clinical outcomes (worsening HF or cardiovascular mortality).
- Dapagliflozin reduced the initiation of uric acid-lowering agent by 57% and treatment with colchicine by 46%.

Dapagliflozin represents an additional clinical benefit in HF due to reduction in the need for initiation of anti-gout medication in such patients.

